Options activity and recent earnings put Haemonetics in focus

Haemonetics (HAE) has moved onto many investors’ watchlists after a jump in implied volatility for its near term options, coming just days after earnings that paired steady sales with weaker profitability.

The stock has been under pressure despite ongoing corporate activity, with the share price down 29.62% year to date and the 1 year total shareholder return declining 19.94%, pointing to fading momentum after recent earnings and buyback updates.

If this kind of mixed sentiment has you rethinking your watchlist, it could be a useful moment to scan for healthcare companies using artificial intelligence by checking out 32 healthcare AI stocks

With Haemonetics trading well below some valuation estimates despite solid revenue and a weaker profit line, options traders are clearly bracing for bigger swings. The key question is whether this represents a mispriced healthcare stock or a market that is already discounting its growth.

Most Popular Narrative: 35.2% Undervalued

With Haemonetics last closing at $56.29 and the most followed fair value estimate sitting at $86.90, the current gap is hard for many investors to ignore, especially with options activity pointing to bigger moves ahead.

Rapid innovation and increased adoption of advanced plasma collection systems (NexSys with Persona and Express Plus), as well as new software contracts securing ~80% market share, are driving share gains and supporting double-digit organic growth ex-CSL in the plasma segment; these trends are expected to boost both revenue and net margins as upgrades and center conversions accelerate through FY26 and into FY27.

Want to see what sits behind that projected value gap? The narrative leans heavily on stronger earnings, higher margins and a future earnings multiple that assumes meaningful execution. Curious how those pieces fit together into an $86.90 fair value and a 35.2% discount today?

Result: Fair Value of $86.90 (UNDERVALUED)

However, there are clear watchpoints, including competition in vascular closure and interventional technologies, as well as Haemonetics' heavy dependence on a few largely U.S. focused products.

Next Steps

With sentiment split between concerns and potential upside, it makes sense to move quickly and examine the underlying data yourself so you can decide where you stand using 2 key rewards and 3 important warning signs

Looking for more investment ideas?

If you stop with just one stock, you could miss opportunities that fit your goals far better. Let the Simply Wall Street Screener do some of the heavy lifting.

• Spot potential bargains early by scanning a focused list of screener containing 21 high quality undiscovered gems that combine quality fundamentals with lower market attention.
• Strengthen your portfolio’s foundation by filtering for companies in the solid balance sheet and fundamentals stocks screener (45 results) that prioritise financial resilience.
• Dial down portfolio swings by zeroing in on 65 resilient stocks with low risk scores that score well on stability and downside protection.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.